Cargando…
Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT
BACKGROUND: The clinical benefit of allergen-specific immunotherapy (AIT) involves induction of blocking antibodies. It is not clear if these antibodies function via steric hindrance alone or a combination of levels, avidities, and epitope specificities, and clinical outcome cannot be predicted. We...
Autores principales: | Huber, Sara, Lang, Roland, Steiner, Markus, Aglas, Lorenz, Ferreira, Fatima, Wallner, Michael, Hawranek, Thomas, Gadermaier, Gabriele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174570/ https://www.ncbi.nlm.nih.gov/pubmed/30338052 http://dx.doi.org/10.1186/s13601-018-0226-7 |
Ejemplares similares
-
High‐affinity Bet v 1‐specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy
por: Huber, Sara, et al.
Publicado: (2021) -
Crystallographically Mapped Ligand Binding Differs in High and Low IgE Binding Isoforms of Birch Pollen Allergen Bet v 1
por: Kofler, Stefan, et al.
Publicado: (2012) -
Glutathione-S-Transferase: A Minor Allergen in Birch Pollen due to Limited Release from Hydrated Pollen
por: Deifl, Stephan, et al.
Publicado: (2014) -
Glutathione-s-transferase is a minor allergen in birch pollen because of restricted release from hydrated pollen grains
por: Deifl, Stephan, et al.
Publicado: (2014) -
Trimolecular complex between major birch pollen allergen, Bet v 1, monoclonal allergen-specific human IgE and recombinant CD23
por: Selb, Regina, et al.
Publicado: (2014)